MONDAY, Feb. 10, 2020 (HealthDay News) — Receipt of one, two, or three doses of the human papillomavirus (HPV) vaccine among females aged 15 to 19 years is associated with reduced incidence of preinvasive cervical disease at five years compared to that seen in unvaccinated females, according to a study published online Feb. 10 in Cancer.
Ana M. Rodriguez, M.D., M.P.H., from the University of Texas Medical Branch at Galveston, and colleagues conducted a retrospective matched cohort study to identify females aged 9 to 26 years who received one or more quadrivalent HPV vaccine doses between January 2006 and June 2015. The association between the number of HPV vaccine doses and incidence of preinvasive cervical disease and high-grade cytology at five-year follow-up was examined.
Data were included for 133,082 females (66,541 vaccinated and 66,541 unvaccinated) who were stratified by the number of doses of HPV vaccine and age at vaccine initiation. The researchers found that the hazard ratio for high-grade cytology was 0.84 for the three-dose group among those aged 15 to 19 years, while the hazard ratios for histologically confirmed preinvasive cervical disease were 0.64, 0.72, and 0.66, respectively, for one, two, and three doses.
“These data add to the growing evidence suggesting that there may truly be no major difference in protection against cervical preinvasive lesions, up to 10 years so far, conferred by one, two, or three doses of HPV vaccination,” write the authors of an accompanying editorial.
The editorial authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Copyright © 2020 HealthDay. All rights reserved.
